| 薛缪群 桑剑锋 苏磊 王雪晨 姚永忠.乳腺癌CXCR1 的表达特征及其与新辅助化疗疗效的相关性[J].现代生物医学进展英文版,2015,15(24):4659-4663. |
| 乳腺癌CXCR1 的表达特征及其与新辅助化疗疗效的相关性 |
| Expression Characteristics of CXCR1 in Breast Carcinoma and the Relevancewith the Effect of Neo-adjuvant Chemotherapy |
| |
| DOI： |
| 中文关键词: 乳腺癌 趋化因子受体 新辅助化疗 靶向治疗 |
| 英文关键词: Breast cancer Chemokine receptor Neo-adjuvant chemotherapy Targeted therapy |
| 基金项目:南京市医学科技发展项目（YKK10080） |
|
| Hits: 921 |
| Download times: 0 |
| 中文摘要: |
| 目的：研究趋化因子受体CXCR1 在乳腺癌组织中的表达特征，并探讨新辅助化疗前后其表达变化与化疗疗效的关系。方
法：选取20 例正常乳腺组织，20 例乳腺纤维腺瘤，104 例乳腺癌标本，免疫组化染色后统计每例标本CXCR1 的阳性表达积分，分
析不同乳腺疾病CXCR1的表达差异。统计新辅助化疗前后乳腺癌标本CXCR1的阳性表达积分的变化，分析其与化疗病理反应
的关系。结果：CXCR1 在正常乳腺组织、乳腺纤维腺瘤中低表达，在乳腺癌组织上高表达；其表达与患者的年龄、原发肿瘤的大小
无关(P>0.05)，与病理分期、癌细胞的分化程度、淋巴结转移个数、激素受体状态及Her2 表达情况相关，P<0.05，有统计学意义。新
辅助化疗后，癌组织中CXCR1 的表达下降，下降幅度越大，其化疗疗效越好。结论：CXCR1的检测对于乳腺疾病的良恶性判断有
指导意义，可辅助判断乳腺癌的恶性程度、侵袭性以及预后，CXCR1 表达的下降与化疗疗效相关，抑制其表达可能可以提高化疗
疗效。 |
| 英文摘要: |
| Objective:To investigate the expression of chemokine receptor CXCR1 in the tissues of breast cancer, before and after
neo-adjuvant chemotherapy, and to analyze the relationship between the expression and the efficacy of neo-adjuvant chemotherapy.Methods:One hundred and four female cases with breast carcinoma, twenty cases with normal breast tissues, and twenty cases with
breast fibroadenoma were collected. Immunohistochemistry was used to detect the expression of CXCR1 in the various tissues, and find
its expression characteristics. The expression of CXCR1 in breast cancer biopsies and surgical specimens and the relationship between
the expression and the efficacy of neo-adjuvant chemotherapy was analyzed.Results:The chemokine receptor CXCR1 was lowly expressed
in normal breast tissue and breast fibrodenoma, but highly expressed in breast cancer. It had no significant correlation with patient's
age, primary tumor size (P>0.05), but was significantly correlated with pathological stage, tumor cell differentiation, as well as the
presence of lymph node metastasis (P<0.05). The expression of CXCR1 in breast cancer declined after neo-adjuvant chemotherapy.
While the expression declined more significantly, the patient had the better efficacy.Conclusion:Chemokine receptor CXCR1 could be
used as an indicator to predict breast disease benign or malignant, auxiliarily to predict the degree of malignancy of breast cancer, its invasive
ability and prognosis. It could be also a good indicator to detect the effect of neo-adjuvant chemotherapy and an effective target for
anti-cancer therapy. |
|
View Full Text
View/Add Comment Download reader |
| Close |
